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1. Introduction
   Today, increase in the number of drug-resistant 
pathogens particularly the acquired multi-drug resistant 
(MDR) strains such as methicillin resistant Staphylococcus 
aureus (MRSA) cause serious public health problem 
throughout the world. On the other hand, the limited 
success of strategies such as combinatorial chemistry in 
providing new agents indicates an uncertain forecast for 
further antimicrobial therapy[1]. Although the majority of 
natural products has been isolated from terrestrial sources, 
but in the last two decade several bioactive substances have 
been isolated from marine bacteria and are new resources 
for the development of medically useful compounds. For 
the first time, in 1947, Rosenfeld and Zobell demonstrated 
that marine bacteria produce antimicrobial substances[2]. 
Nowadays, several antibiotic compounds from marine 
microorganisms have been reported, including Pyron 
from Pseudomonas[3], Loloatin from Bacillus[4], Tiomarinol 
from Altromonas[5], Marinopyrroles from Streptomyces[6], 
Agrochelin from Agrobacterium [7], Koromicin from 
Pseudoalteromonas[8] and Pelagiomicin from Pelagiobacter 
variabilis[9] and so on. Because of the enormous biodiversity 
in the marine environment, in the case of microorganisms, 
sea water is composed of 78 million microscopic cell per 
ounce or the bottom, which mimic the soil, contain more 
than 1 billion cells in the volume of an ordinary cube of 
sugar[10]; this environment as an amuzing unique community 
provides the most prolific sources for new natural drugs. 
The present investigation was focused on the isolation of 
potent antibiotic-producing bacteria from several water and 
sediment samples collected form the Persian Gulf.
2. Materials and methods    
2.1. Sampling procedure
  From March to June 2009, samples were collected from 
surface seawater, deep seawater, coastal seawater, marine 
bed sediment and mangrove forest sediment at 18 study 
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sites in the some northern areas of Persian Gulf, including 
Mahshahr port, Bahrakan port and Qeshm Island. Water 
samples were collected by niskin bottles (water sampler) 
which were sterilized by 75% ethanol prior to water 
collection and washed by seawater. Samples were collected 
by water sampler in sterilized glass bottles. Sediments were 
collected by sterilized van veen grab in sterilized plastic 
bags. All of the samples were kept at 4 曟 up to reach to the 
laboratory. 
2.2. Isolation of bacterial strains from marine samples
  The water samples (8 毺L) were inoculated into Marine 
Agar 2216 (High Media). Sediment samples after making 
serial dilution using sterilized sea water were spread on the 
entire surface of Marine Agar 2216. After incubation at 28 曟 
for 3 days, bacterial colonies with different morphology and 
pigmentation were chosen for further process. 
2.3. Preparation of extract
  Pure colonies of bacterial isolates were transferred to 
Erlenmeyer flasks containing Marine Broth (Laboratorios 
CONDA) medium and were incubated on a rotatory shaker 
(150 rpm) at 28 曟 to produce secondary metabolites. 
After 2-7 days, the broth culture first was centrifuged at 
1 300 rpm (伊g) for 20 mins at 4 曟, and then supernatant 
was extracted using same volume of ethyl acetate (EtoAc). 
Solvent was removed at 37 曟.
2.4. Antibacterial activity assay
  All of the test strains were grown in Muller Hinton Broth 
(MHB, Merck) medium at 37 曟 for 24 hrs. Final inoculums 
sizes were adjusted to 108 cfu/mL with reference to the 
McFarland turbidometery[11,12]. Antibacterial activity 
was assessed two times by disc diffusion method on 
Mulller Hinton Agar (MHA, Merck) using gram positive 
bacteria including MRSA, Staphylococcus epidermidis (S. 
epidermidis), Bacillus anthracis (B. anthracis), Bacillus 
cereus (B. cereu), Bacillus pumilus (B. pumilus), Listeria 
monocytogenes (L. monocytogenes), Streptococcus pyogenes 
(S. pyogenes) and gram negative bacteria including 
Pseudomonas aeruginosa (P. aeruginosa), Escherichia coli 
(E. coli), Proteus mirabilis ( P. mirabilis), Salmonella typhi 
(S. typhi) and Klebsiella pneumoniae (K. pneumoniae) as test 
microorganisms. The dried crude extract was dissolved in 
methanol to a concentration of 100 mg/mL. 35 毺L volume 
samples were added to the sterile filter paper disc (6 mm 
in diameter) to assay  the antibacterial activity[13], and the 
disc was dried for 30 mins. Then, discs were placed on 
lawn cultures. Zone of inhibition was measured in mm after 
incubation for 24 hrs at 37 曟. Eight different antibiotics 
including Vancomycin (VA) 30 mcg, Erythromycin (E) 
15 mcg, Methicillin (MT) 5 mcg, Carbenicillin (CB) 100 
mcg, Nitrofurantion (NF) 300 mcg, Penicillin (P) 10 mcg, 
Oxacillin (OX) 1 mcg and Streptomycin (s) 10 mcg were 
used as control. All these synthetic antibiotic discs were 
produced by Difco.
2.5. Effect of the time and temperature on the production of 
antibacterial metabolite
  To find out the optimum temperature for production of 
antibacterial metabolite by isolated marine bacterium, 
this bacterium was grown in Erlenmeyer flasks containing 
Marine Broth at 25 曟, 28 曟, 31 曟, 34 曟, 37 曟, 40 曟 and 
43 曟; after 3 days, ethyl acetate extract prepared from each 
flask was tested at 100 mg/mL concentration against MRSA. 
Also, for determination of optimum intubation time, this 
isolate was grown in Marine Broth at optimum temperature 
and samples were harvested after every 12 hrs from 0 till 
120 hrs, and then ethyl acetate extract prepared from each 
sample was tested at 100 mg/mL against MRSA.   
2.6. Heat and protease treatment on antibacterial metabolite
  To find out thermostability of this antibacterial metabolite, 
1 mL of supernatant was harvested from broth culture and 
treated by temperature at 25 曟, 37 曟, 56 曟, 70 曟 and 
90 曟for 10 mins and 120 曟 for 15 mins; also 200 毺L of 
supernatant was treated by 20 毺L of pepsin (Merck) at final 
concentration 100 mg/mL[14]. Finally, the result of these 
treatments was found by measurement of the inhibition zone 
against MRSA.  
2.7. Identification of antibiotic-producing strain
  The isolated marine bacterial strain with antibacterial 
activity was identified to the species level by observing its 
morphology and biochemical reactions according to the 
methods described by Lyudmila et al and Bergey's manual 
for systematic of bacteriology[15,16].
3. Results
3.1. Isolation and identification of antibiotic-producing 
strain
  Overall, 46 strains of marine bacteria were isolated from 
water and sediment samples of the Persian Gulf, but only 
one brown-pigmented bacterium isolated from a marine 
sediment sample collected at a depth of 10 m was exhibited 
the capability of producing antibiotic compounds (Table 1). 
On the basis of biochemical diagnostic tests (Table 2), this 
bacterium was identified as Pseudomonas aeruginosa PG-01.
3.2. Antibacterial activity test
  The antibacterial compound produced by intended 
bacterium was effective against all of the tested gram 
positive bacteria while gram negative bacteria showed 
resistance to it (Table 1). MRSA, S. pyogenes, S. epidermidis 
and B. cereus exhibited the most sensitivity to Pseudomonas 
aeruginosa PG-01. All tested bacteria were resistant to 
Oxacillin and Penicillin and most of the bacterial species 
were resistance to Methicillin. The inhibition zone diameter 
for Vancomycin and Pseudomonas aeruginosa PG-01 
against MRSA were 22 and 30 mm (Figure1), respectively. 
3.3. Optimization of temperature and time for production of 
antagonistic action in Pseudomonas aeruginosa PG-01
  Results of the effect of time and temperature on the 
production of antibacterial metabolite based on disc 
diffusion showed that although Pseudomonas aeruginosa 
PG-01 was able to grow from 25 曟 to 43 曟, the optimum 
temperature for production of the antagonistic component 
was 37 曟 (Figure 2), with a maximum inhibitory zone of 33 
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mm on the 5th days; also, maximum antibacterial compound 
production  at 37 曟 temperature was achierved in 72 hrs 
culture-old broth (Figure 3).  
Figure 1. Antibacterial activity of ethyl acetate extract of 
Pseudomonas aeruginosa PG-01 against MRSA.
3.4. Preliminary characterization of antibacterial metabolite
  The antibacterial component didn't completely loose its 
activity even after the cell free supernatant was autoclaved 
for 15 mins at 121 曟. The zone of inhibition produced 
by heat-treated culture supernatant decreased to 14 mm, 
compared to the control (28 mm at 24 曟) (Figure 4). The 
antibacterial activity of the cell free supernatant was not 
affected after enzymatic treatment. The zone of inhibition 
(28 mm) observed after treatment with the Pepsin was 
equal to the untreated cell free supernatant that served as a 
control. 
Figure 2. Effect of temperature on production of antibacterial 
metabolite by Pseudomonas aeruginosa PG-01.
DIZ: Diameter of Inhibition Zone.
Figure 3. Effect of time on production of antibacterial metabolite by 
Pseudomonas aeruginosa PG-01.
DIZ: Diameter of Inhibition Zone.
Table 1 
Inhibition zones of ethyl acetate extract of Pseudomonas aeruginosa PG-01 against some clinical pathogens compared with commercial 
antibiotics (mm)*.
Bacterial species(100 mg/mL) Antibiotics Disc (mm)
NF VA CB P FM MT OX S E
B. pumilus   16 15 13 R 17 23 R 16 15
B. anthracis 18 20 16 R 21 23 R 14 21
B. cereus 20 15 12 R 18 R R 15 15
S. aureus 30 22 31 R R R R 12 16
S. epidermidis 27 14 25 R 23 R R 13 14
Str. Pyogenes 32 18 26 R 23 R R 18 25
E. coli R R 22 R 20 R R R R
S. typhi R 10 28 R 21 R R R R
P. mirabilis R 24 28 R 10 R R R R
K. pneumoiae R 13 26 R 18 R R R R
P. aeruginosa R R 25 R R R R R R
*: (6mm) diameter disc;
R: Resistant; -: Not used.
Table 2 
Biochemical tests of antibiotic-producing bacterium isolated from 
sediment of Persian Gulf, Iran.
Test Result Test Result
Gram's reaction - Acid from
Cell shape rod D-glucose +
Motility + L-arabinose -
Indol production - D-mannitol -
O-F test + Maltose -
Catalase + Xylose +
Oxidase + Growth at 4  曟 -
Citrate Utilization + Growth at 42 曟 +
Urease + Growth at 8% Nacl -
Nitrate reduction + Sensitivity to antibiotics
Gelatin hydrolysis + Penicillin -
TSI + Tetracylnine -
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Figure 4. Results of heat treatment on antimicrobial compound 
produced by marine Pseudomonas aeruginosa PG-01.
DIZ: Diameter of Inhibition Zone.
4. Discussion
  The emergence of resistant strains to commonly 
used antibiotics among human microbial pathogens 
has necessitated the researches to discovery the new 
antimicrobial agents that are produced in natural way. The 
oceans, which cover almost 70% of the earth's surface[17], 
contain a variety species, many of which have no terrestrial 
counterparts. So, marine bacteria as a largely untapped 
source are a good choice for searching novel biologically 
active secondary metabolites. In the present study, we have 
attempts to isolate marine antibiotic-producing bacteria 
from the Persian Gulf, as an untapped source for searching 
new natural drugs. Among the isolates, only one bacterium 
identified as Pseudomonas aeruginosa PG-01 was found to 
be effective against clinical pathogens. Pseudomonas are 
well-known widespread microorganism, which have been 
isolated from variety of natural sources, soil, plants, mineral 
waters and clinical specimen and they are characterized by 
a high level of metabolic diversity[15]. Based on these results, 
the antibacterial compound produced by Pseudomonas 
aeruginosa PG-01 had antibacterial effect on all of the 
tested gram-positive bacteria while all of the gram-
negative bacteria were resistant to it. This difference may 
be due to several possible reasons such as permeability 
barrier provided by the presence of cell wall with multilayer 
structure in gram-negative bacteria or the membrane 
accumulation mechanisms or presence of enzymes in 
periplasmic space which are able to break down foreign 
molecules introduced from outside[18]. Antibacterial activity 
of intended marine isolate against MRSA was remarkable, 
while this strain was resistant to broad spectrum antibiotics, 
so, this suggests new hopes for treatment of the infections 
caused by MRSA. Furthermore, all of the tested bacillus 
strains as resistant spore forming bacteria showed a high 
degree of sensitivity to the raw extract of Pseudomonas 
aeruginosa PG-01; so, the active compound from this 
extract can be used as antiseptic compound. Treatment of 
the cell free supernatant with Pepsin or heating even up to 
121 曟 didn't cause to active supernatant completely loose 
its activity. These results show that the active constituent 
of the antibiotic produced by Pseudomonas aeruginosa 
PG-01 maybe not proteinaceous in nature, like these 
results about of antibacterial compounds produced by 
Pseudomonas sp. has been reported previously[19,20]. Finally, 
Comparing the antibacterial effect of the obtained extract 
from Pseudomonas sp. PG-01 especially against MRSA, it 
can regard the intended bacterium as a valuable strain and 
further studies should be performed in order to purify and 
identify the chemical structure of its antimicrobial compound. 
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